Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.98% is 99% below its 5-year average of 711.96%, near the low end of its 5-year range (3.87%–4507.18%).
As of the fiscal period ended Tuesday, June 30, 2026. 37.60% below its 12-month average of 6.38%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2026 (2026-06-30): 3.98%.
DEBT TO ASSETS RATIO
3.98%
DEBT TO ASSETS RATIO AVG TTM
6.38%
DEBT TO ASSETS RATIO AVG 3Y
663.07%
DEBT TO ASSETS RATIO AVG 5Y
711.96%
DEBT TO ASSETS RATIO AVG 10Y
1761.60%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-37.60%
CURRENT VS 3Y AVG
-99.40%
CURRENT VS 5Y AVG
-99.44%
CURRENT VS 10Y AVG
-99.77%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+4326.36%
vs the sector median at left
Propanc Biopharma, Inc.
Market Cap
$1.15M
Debt to Assets Ratio
3.98%
TTM Avg
6.38%
3Y Avg
663.07%
5Y Avg
711.96%
Market Cap
$1.11M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.31M
Debt to Assets Ratio
0.47%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.15M | 3.98% | 6.38% | 663.07% | 711.96% |
| IM Cannabis Corp. (IMCC)vs › | $1.14M | 0.56% | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | 0.10% | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | 0.11% | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.31M | 0.47% | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 0.00% | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.33M | 0.04% | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | 0.01% | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.35M | 0.00% | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | 0.15% | N/A | N/A | N/A |
Debt/Assets
4.0%
Debt/Equity
0.05
Current Ratio
2.55
Interest Coverage
-42.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.98% |
| 2026-03-31 | 10.98% |
| 2025-12-31 | 4.30% |
| 2025-09-30 | 3.87% |
| 2025-06-30 | 8.80% |
| 2025-03-31 | 5.54% |
| 2024-12-31 | 1539.52% |
| 2024-09-30 | 1733.57% |
| 2024-06-30 | 1310.40% |
| 2024-03-31 | 2496.87% |
| 2023-12-31 | 420.79% |
| 2023-09-30 | 285.64% |
| 2023-06-30 | 795.60% |
| 2023-03-31 | 430.38% |
| 2022-12-31 | 686.40% |
| 2022-09-30 | 974.60% |
| 2022-06-30 | 1211.70% |
| 2022-03-31 | 600.81% |
| 2021-12-31 | 835.13% |
| 2021-09-30 | 880.33% |
| 2021-06-30 | 4507.18% |
| 2021-03-31 | 3325.51% |
| 2020-12-31 | 2852.24% |
| 2020-09-30 | 1262.37% |
| 2020-06-30 | 1525.31% |
| 2020-03-31 | 4104.89% |
| 2019-12-31 | 4263.00% |
| 2019-09-30 | 1250.67% |
| 2019-06-30 | 1532.22% |
| 2019-03-31 | 762.61% |
| 2018-12-31 | 380.99% |
| 2018-09-30 | 4394.27% |
| 2018-06-30 | 6374.23% |
| 2018-03-31 | 3964.50% |
| 2017-12-31 | 3323.32% |
| 2017-09-30 | 2864.89% |
| 2017-06-30 | 3571.95% |
| 2017-03-31 | 5835.67% |
| 2016-12-31 | 1335.33% |
| 2016-09-30 | 268.35% |
| 2016-06-30 | 286.95% |
